COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy

Thromb Res. 2020 Dec;196:483-485. doi: 10.1016/j.thromres.2020.10.004. Epub 2020 Oct 15.

ABSTRACT

1. •

   COVID-19 patients are at increased risk of thromboembolic complications.

2. •

   Escalated-dose thromboprophylaxis may help reduce the rate of thromboembolic events.

3. •

   The bleeding risk is highest for patients treated with therapeutic anticoagulation.

PMID:33091700 | PMC:PMC7557260 | DOI:10.1016/j.thromres.2020.10.004